Relacorilant
Relacorilant is a small molecule pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
23 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cushing syndrome | D003480 | EFO_0003099 | E24 | 1 | 2 | 2 | — | — | 5 |
| Pituitary acth hypersecretion | D047748 | EFO_1001110 | E24.0 | 1 | 2 | 1 | — | — | 4 |
| Neoplasms | D009369 | — | C80 | 2 | 1 | 1 | — | — | 3 |
| Syndrome | D013577 | — | — | — | 2 | 1 | — | — | 3 |
| Adenocarcinoma | D000230 | — | — | — | 1 | 1 | — | — | 2 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | 1 | — | — | 2 |
| Fallopian tube neoplasms | D005185 | — | — | — | 1 | 1 | — | — | 2 |
| Pancreatic ductal carcinoma | D021441 | — | — | — | — | 1 | — | — | 1 |
| Adenoma | D000236 | — | — | — | — | 1 | — | — | 1 |
| Adrenocortical adenoma | D018246 | — | — | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Carcinoma | D002277 | — | C80.0 | 1 | 1 | — | — | — | 2 |
| Prostatic neoplasms | D011471 | — | C61 | 1 | 1 | — | — | — | 2 |
| Recurrence | D012008 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 10 | — | — | — | — | 10 |
| Adrenocortical carcinoma | D018268 | — | — | 1 | — | — | — | — | 1 |
| Food-drug interactions | D018565 | — | — | 1 | — | — | — | — | 1 |
| Liver diseases | D008107 | HP_0002910 | K70-K77 | 1 | — | — | — | — | 1 |
| Hepatic insufficiency | D048550 | — | — | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Relacorilant |
| INN | relacorilant |
| Description | Relacorilant (developmental code name CORT-125134) is an antiglucocorticoid which is under development by Corcept Therapeutics for the treatment of Cushing's syndrome. It is also under development for the treatment of solid tumors and alcoholism. The drug is a nonsteroidal compound and acts as an antagonist of the glucocorticoid receptor. As of December 2017, it is in phase II clinical trials for Cushing's syndrome and phase I/II clinical studies for solid tumors, while the clinical phase for alcoholism is unknown.
|
| Classification | Small molecule |
| Drug class | glucocorticoid receptor antagonists (not glucocorticoids) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | Cn1cc(S(=O)(=O)N2CCC3=Cc4c(cnn4-c4ccc(F)cc4)C[C@]3(C(=O)c3cc(C(F)(F)F)ccn3)C2)cn1 |
Identifiers
| PDB | — |
| CAS-ID | 1496510-51-0 |
| RxCUI | — |
| ChEMBL ID | CHEMBL4068611 |
| ChEBI ID | — |
| PubChem CID | 73051463 |
| DrugBank | — |
| UNII ID | 2158753C7E (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 135 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
0 adverse events reported
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use